Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2020-04-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于募集资金2019年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a public offering. It includes specifics on the amount raised, the allocation and usage of these funds, changes in investment projects, compliance with regulatory requirements, and approvals by the board and shareholders. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "专项报告" (special report) on the annual storage and use of raised funds for the year 2019. This type of document corresponds to a Capital/Financing Update as it focuses on fundraising, capital usage, and related financial management rather than a full annual report or earnings release. The document length and content confirm it is the report itself, not just an announcement of a report.
2020-04-27 Chinese
2019年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2019 年年度报告摘要" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2019 Annual Report Summary." It contains detailed financial data for the year 2019, including revenue, net profit, earnings per share, and other financial indicators. It also discusses business operations, product lines, shareholder information, accounting policy changes, and management discussions. The document is over 11,000 characters long, indicating it is a substantive report rather than a brief announcement. The content and structure align with an Annual Report, which covers company activity and full financial performance for the fiscal year. Therefore, the document should be classified as an Annual Report (10-K). FY 2019
2020-04-27 Chinese
关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (861 characters) about the company receiving a government subsidy. It explains the nature of the subsidy, its accounting treatment, and its expected impact on profits. There is no detailed financial data or comprehensive report content. The document is a disclosure announcement related to government grants, not a full financial report or audit. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is an announcement of a specific event affecting financials, best classified under Regulatory Filings (RNS) as it is a regulatory disclosure without detailed financial statements.
2020-04-23 Chinese
关于全资子公司米格列醇片通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its wholly-owned subsidiary's pharmaceutical product passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug's background, approval, and potential impact on the company. The document is relatively short (1752 characters) and serves as a formal disclosure of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it contains substantive information about the approval and its implications. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about product approval and company impact without fitting into other specific categories like earnings, management changes, or capital updates.
2020-04-21 Chinese
关于持股5%以上股东减持比例达到1%暨减持计划数量过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from a company regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the progress of the share reduction plan, including specific dates, quantities, and prices of shares sold. The document references compliance with securities laws and regulations related to shareholder share reduction. There is no indication of financial statements, earnings data, or management discussion. The content focuses on the shareholder's transaction and the progress of the share reduction plan. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2020-04-20 Chinese
关于董事股份减持计划的预披露公告
Director's Dealing Classification · 100% confidence The document is a disclosure announcement regarding a director's plan to reduce their shareholding in the company. It details the shareholder's name, shareholding percentage, planned reduction amount, reasons for reduction, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report attached. The document fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives.
2020-03-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.